Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brenetafusp plus Nivolumab in HLA-A*02:01-positive advanced melanoma
NCT06112314Phase 3Recruiting
- Sponsor
- Immunocore
- Start
- Jun 2024
- Primary completion
- Oct 2027
- Modality
- Bispecific Antibodies, T-cell Engagers, Fc-Fusion Proteins
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of brenetafusp in melanoma, sponsored by Immunocore. Primary endpoint: Progression-Free Survival at 45 months. Started Jun 2024; status: recruiting.
02
Drugs
brenetafusp
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06112314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06112314.